Literature DB >> 320015

Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.

J Hulting, B Jansson.   

Abstract

Ten patients with various heart diseases and ventricular arrhythmia received a single oral dose of disopyramide (DE) 200 mg. The ECG was recorded continuously for about 50 h from 2-4 h before drug administration. A statistically significant reduction in the number of ventricular ectopic beats (VEBs) was seen 1.0-3.5 h after drug intake; the average number of VEBs per 30 min decreased from 317 during the control period to 92 by 1.0-3.5 h after treatment and if one patient who did not respond is excluded, the corresponding figures were 272 and 14, respectively. Consecutive VEBs were seen in seven patients before DE was given and decreased significantly (p less than 0.05) 1.5-5.5 h after drug administration. There was no change in the PQ interval, the QRS interval showed a slight increase, whereas the QT interval was prolonged 0.5-4 h after administration of DE. A specific gas chromatographic method was used for DE assay in plasma and urine. Absorption was rapid in all patients. Urinary excretion during the first 48 h after drug intake varied between 35 and 75%. The lowest effective antiarrhythmic concentration estimated in six patients ranged from 1.4 to 7.0 mug/ml. beta-Phase half-life in five patients was between 10.3 and 22.1 h.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 320015     DOI: 10.1007/bf00562898

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine.

Authors:  T C Hutsell; S J Stachelski
Journal:  J Chromatogr       Date:  1975-03-19

3.  A nomogram for rate correction of the Q-T interval in the electrocardiogram.

Authors:  M KISSIN; M M SCHWARZCHILD; H BAKST
Journal:  Am Heart J       Date:  1948-06       Impact factor: 4.749

4.  Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug.

Authors:  L A Vismara; D T Mason; E A Amsterdam
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

5.  Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia.

Authors:  J Hulting; G Rosenhamer
Journal:  Acta Med Scand       Date:  1976

6.  The reliability of intermittent ECG sampling in arrhythmia detection.

Authors:  L Rydén; A Waldenström; S Homberg
Journal:  Circulation       Date:  1975-10       Impact factor: 29.690

7.  Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.

Authors:  G Jennings; M S Jones; E M Besterman; D G Model; P P Turner; P H Kidner
Journal:  Lancet       Date:  1976-01-10       Impact factor: 79.321

8.  Disopyramide: serum level and arrhythmia conversion.

Authors:  A P Niarchos
Journal:  Am Heart J       Date:  1976-07       Impact factor: 4.749

  8 in total
  7 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

3.  Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.

Authors:  G Forssell; C Graffner; R Nordlander; O Nyquist
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

4.  Cardiovascular effects of acute normovolemic hemodilution in rats with disopyramide-induced myocardial depression.

Authors:  F G Estafanous; C E Smith; W M Selim; R C Tarazi
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

5.  Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity.

Authors:  E Winslow
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

Review 6.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 7.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.